? Shared Resource Management The ACC Shared Resources provide access to specialized technologies, services, training and expertise critical to accelerate research productivity for the 324 ACC members. Each Shared Resource engages with ACC members, trainees, and staff to catalyze basic, translational, clinical and population science cancer research, provide user training and support grant applications for extramural funding and publication of high impact papers. Under the direction of Dr. Celeste Simon, Associate Director for Shared Resources, they are continuously evaluated to ensure that they provide cutting edge technologies and accessible, cost-effective and reliable services that serve the needs of the ACC membership. We propose the following three aims: 1) Support high quality Shared Resources that serve the scientific needs of the ACC membership and catalyze impactful research activity; 2) Ensure stability of and access to ACC and institutional Shared Resources through responsible fiscal management and over-arching usage policies; and 3) Determine the scientific priorities of ACC members and ensure current and future Shared Resources meet membership needs. ACC Administration works closely with ACC Leadership and Dr. Simon in assessing Shared Resources, overseeing management, and ensuring fiscal stability, cost-effectiveness and opportunities for growth. Fiscal oversight of Shared Resources is accomplished through a suite of applications (Path BioResource system), centrally managed by the Perelman School of Medicine (PSOM) and ACC Administration. Strategic planning is regularly undertaken; user feedback and internal advisory boards for each Shared Resources guarantee cutting-edge quality. The percentage of ACC users for each Shared Resource ranges from 32%-100%; the percentage of annual budget support provided through CCSG to support each Shared Resource ranges from 7% to 34%. For the current funding period, we are proposing nine Full Shared Resources ? ACC BioRepository, Biostatistics and Bioinformatics, Comparative Pathology, Flow Cytometry and Cell Sorting, Genomic Analysis, Human Immunology, Metabolomics, Small Animal Imaging, and Transgenic and Chimeric Mouse Facilities. Based on our strategic planning process and in response to members' scientific needs, two of these Shared Resources (ACC BioRepository; Metabolomics) are new, each emerging from Developing Shared Resources of the current funding period. One existing Shared Resource has been expanded in scope (from the Biostatistics Core to the Biostatistics and Bioinformatics Core). Two Developing Shared Resources (Small Animal Radiation and Electronic Phenotyping) are being proposed, based on ACC membership needs. ACC members can utilize over 75 Core Facilities at PSOM; 24 of these undergo formal review by the PSOM Biomedical Research Core Facilities Committee to assure quality. Through ACC support of Shared Resources, members have access to state-of the-art equipment and instrumentation, technical expertise, training and education, all designed to support innovative cutting-edge cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016520-45
Application #
10088754
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-15
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Huang, Mo; Wang, Jingshu; Torre, Eduardo et al. (2018) SAVER: gene expression recovery for single-cell RNA sequencing. Nat Methods 15:539-542
Yam, Clinton; Xu, Xiaowei; Davies, Michael A et al. (2018) A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clin Cancer Res 24:22-32
Onorati, Angelique V; Dyczynski, Matheus; Ojha, Rani et al. (2018) Targeting autophagy in cancer. Cancer 124:3307-3318
Rebecca, Vito W; Nicastri, Michael C; Fennelly, Colin et al. (2018) PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discov :
Garfall, Alfred L; Stadtmauer, Edward A; Hwang, Wei-Ting et al. (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3:
Jang, Jeong Hoon; Manatunga, Amita K; Taylor, Andrew T et al. (2018) Overall indices for assessing agreement among multiple raters. Stat Med 37:4200-4215
Scheel, John R; Kim, Eunhee; Partridge, Savannah C et al. (2018) MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial. AJR Am J Roentgenol 210:1376-1385
Romero, Sally A D; Brown, Justin C; Bauml, Joshua M et al. (2018) Barriers to physical activity: a study of academic and community cancer survivors with pain. J Cancer Surviv 12:744-752
Hinderer, Christian; Katz, Nathan; Buza, Elizabeth L et al. (2018) Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum Gene Ther 29:285-298
Li, Jinyang; Byrne, Katelyn T; Yan, Fangxue et al. (2018) Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 49:178-193.e7

Showing the most recent 10 out of 1047 publications